Anaphylactic Shock to Lidocaine: A Rare Case With Evaluation of Cross-Reactivity Between Local Anesthetics

Lopes, Jorge; Ferreira, Ana Reis; Sousa, Maria João; Cadinha, Susana

doi:10.18176/jiaci.0658

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case was reported by Li M et al [32] who described the occurrence of a fatal anaphylaxis that, according to medical records, autopsy, and laboratory findings, was determined by the Botox-lidocaine mixture. Cases of anaphylactic shock to lidocaine have been previously reported [33,34] and among the life-threating cases described in our study there was an ICSR describing the occurrence of angioedema in a woman receiving BTA, tozinameran, hyaluronic acid, and lidocaine. Thus, although local allergic reactions (presenting with edema, erythema or redness) seem to be the most common BTA-induced ADRs, a risk of diffuse erythema, urticaria, and anaphylactic shock cannot be excluded [35].…”

Section: Discussionsupporting

confidence: 56%

Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System

Nicoletti,

Anatriello,

Liguori

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Botulinum toxin is a protein deriving from the bacteria Clostridium botulinum and it is widely used for the treatment of a variety of muscle hyperactivity syndromes and for cosmetic indications. Having a long-lasting effect, Botulinum toxin type A (BTA) is one of the most botulin toxin products used. Even if BTA has shown benefits in reducing the vertical lines between the eyebrows, Adverse Drug Reactions (ADRs) have been experienced as well, of which the most common ones are headache and drooping eyelids. In addition, since other local and systemic risks have been identified, a non-interventional post-authorization safety study (PASS) has been started. The aim of the present study was to report cases of skin toxicity associated with this drug, considering Individual Case Safety Reports (ICSRs) existing on the Eudravigilance website. Among 1464 ICSRs sent to the EV database, 718 ICSRs, including 5154 PTs, reported BTA as a suspected drug associated with cutaneous toxicity. The majority of patients experiencing BTA-induced skin toxicity were female (92.1%) belonging mostly to the age group of 18–64 years. The most serious criteria, when reported, were “Other Medically Important Condition” and “Caused/prolonged hospitalization”, although the outcome was mainly reported as “Unknown”. The most reported PTs, related to skin disorders, were: “Erythema”, “Rash”, “Pruritus”, “Urticaria”, “Swelling face”, “Brow ptosis”, “Eyelid ptosis”, “Injection site pain”, and “Angioedema”. Considering that in most ICSRs, ADRs related to skin disorders were symptoms of hypersensitivity reactions which in some conditions could be life-threatening, further studies are required to better define the safety profile of BTA used for aesthetic procedures.

show abstract

Section: Discussionsupporting

confidence: 56%

Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System

Nicoletti,

Anatriello,

Liguori

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…It was essential to study possible cross reactivity between lidocaine and other amide-(bupivacaine) and/or ester-anaesthetics (tetracaine). In fact, cross reactivity has been demonstrated previously between amides (mepivacaineand lidocaine) [5]. Herewe observed a good tolerance to bupivacaine, despite cross reactivity between lidocaine and bupivacaine having been described in a previous study [6].…”

supporting

confidence: 57%

Kounis Syndrome After Lidocaine Use

Garcia-Nunez¹,

Algaba-Marmol²,

Ignacio-Garcia³

2023

J Investig Allergol Clin

View full text Add to dashboard Cite

“…40 There are almost no reports of true anaphylaxis that seem credible. 41 Within the past 10 years, 9 case reports have reported anaphylaxis. However, incomplete details or other variables make it difficult to attribute anaphylaxis entirely to lidocaine.…”

Section: Potential Adverse Reactions To Lidocaine and Their Treatmentmentioning

confidence: 99%

Clinically Important Pharmacologic Considerations for Wide Awake Local No Tourniquet (WALANT) Hand Surgery

Janes

Sepehripour

Lalonde

2023

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Summary: Understanding the clinically important pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) of medications used in surgery will help surgeons use them more safely and effectively. The goal of this article is to provide an overview of these considerations for the 2 medications used in wide-awake local anesthesia with no tourniquet upper extremity surgery (ie, lidocaine and epinephrine) to establish a better understanding of lidocaine and epinephrine in tumescent local anesthesia, as well as adverse reactions and how to manage them.

show abstract

Anaphylactic Shock to Lidocaine: A Rare Case With Evaluation of Cross-Reactivity Between Local Anesthetics

Cited by 5 publications

References 0 publications

Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System

Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System

Kounis Syndrome After Lidocaine Use

Clinically Important Pharmacologic Considerations for Wide Awake Local No Tourniquet (WALANT) Hand Surgery

Contact Info

Product

Resources

About